Results 41 to 50 of about 12,785,139 (351)

The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces. [PDF]

PLoS ONE, 2015
The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy
Caileen M Brison, Steven M Mullen, Michelle E Wuerth, Kira Podolsky, Matthew Cook, Jacob A Herman, Justin D Walter, Shannon L Meeks, P Clint Spiegel   +8 more
doaj   +1 more source

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice

Haematologica, 2018
Immune responses to factor VIII remain the greatest complication in the treatment of severe hemophilia A. Recent epidemiological evidence has highlighted that recombinant factor VIII produced in baby hamster kidney cells is more immunogenic than factor ...
Jesse D. Lai, Laura L. Swystun, Dominique Cartier, Kate Nesbitt, Cunjie Zhang, Christine Hough, James W. Dennis, David Lillicrap   +7 more
doaj   +1 more source

Desmopressin in moderate hemophilia A patients: a treatment worth considering

Haematologica, 2018
Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed.
Janneke I. Loomans, Marieke J.H.A. Kruip, Manuel Carcao, Shannon Jackson, Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Helen Platokouki, Erik Beckers, Jan Voorberg, Johanna G. van der Bom, Karin Fijnvandraat, for the RISE consortium   +12 more
doaj   +1 more source

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

Haematologica, 2020
During factor VIII prophylaxis for severe hemophilia A, bleeding risk increases with time when factor VIII activity is below 1%. Maintaining trough activity above 1% does not protect all patients from bleeding.
Andreas Tiede, Faraizah Abdul Karim, Victor Jiménez-Yuste, Robert Klamroth, Sandra Lejniece, Takashi Suzuki, Andreas Groth, Elena Santagostino   +7 more
doaj   +1 more source

An Adaptive Management Model for Brown Bears in Hokkaido: Based on Total Population and the Number of Nuisance Bears

Population Ecology, EarlyView.
Bear management changes management actions according to the horizontal axis of the population size and the vertical axis of the number of nuisance bears. Aiming for the target population size of Ntar, Actions I and II protect the bears, and Action IV reduces the population.
Hiroyuki Matsuda, Akira Maki, Tsutomu Mano, Hifumi Tsuruga, Hino Takafumi, Shinichi Horino   +5 more
wiley   +1 more source

Assessing the value of bypassing agent therapy used prophylactic versus on-demand, during immune tolerance induction for treatment of inhibitors: a retrospective chart review

Orphanet Journal of Rare Diseases, 2023
Background Haemophilia A is a bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) which leads to severe and repeated bleedings. There is a need to understand the optimal treatment pathway for FVIII inhibitors with the use of immune ...
George Morgan, Emily Back, Doug Rosa, Jamie O’Hara, Alan Finnegan   +4 more
doaj   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Exploring lipid diversity and minimalism to define membrane requirements for synthetic cells

FEBS Letters, EarlyView.
Designing the lipid membrane of synthetic cells is a complex task, in which its various roles (among them solute transport, membrane protein support, and self‐replication) should all be integrated. In this review, we report the latest top‐down and bottom‐up advances and discuss compatibility and complexity issues of current engineering approaches ...
Sergiy Gan, Victoria Scarpelli, Marten Exterkate   +2 more
wiley   +1 more source

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

Journal of Blood Medicine, 2020
Renchi Yang,1 Yongqiang Zhao,2 Xuefeng Wang,3 Jing Sun,4 Runhui Wu,5 Chenghao Jin,6 Jie Jin,7 Depei Wu,8 Pablo Rendo,9 Feifei Sun,10 Jeremy Rupon,9 Francois Huard11,†, Joan M Korth-Bradley,12 Lihong Xu,10 Binyu Luo,10 Yingxue Cathy Liu13 ...
Yang R, Zhao Y, Wang X, Sun J, Wu R, Jin C, Jin J, Wu D, Rendo P, Sun F, Rupon J, Huard F, Korth-Bradley JM, Xu L, Luo B, Liu YC   +15 more
doaj  

Imbalance of pro- vs. anti-coagulation factors in Chinese patients with Budd-Chiari syndrome and non-cirrhotic portal vein thrombosis. [PDF]

PLoS ONE, 2015
The coagulation abnormalities in non-cirrhotic Budd-Chiari syndrome (NC-BCS) and non-cirrhotic portal vein thrombosis (NC-PVT) are unclear. We conducted this case-control study to investigate the coagulation profile of NC-BCS and NC-PVT in Chinese ...
Hui Chen, Lei Liu, Xingshun Qi, Chuangye He, Zhanxin Yin, Feifei Wu, Daiming Fan, Guohong Han   +7 more
doaj   +1 more source